MXLIPO
MCID: MYX005
MIFTS: 60

Myxoid Liposarcoma (MXLIPO)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Myxoid Liposarcoma

MalaCards integrated aliases for Myxoid Liposarcoma:

Name: Myxoid Liposarcoma 58 12 77 54 76 38 30 13 15 17
Myxoid/round Cell Liposarcoma 54 60 74
Liposarcoma, Myxoid 45 41 74
Liposarcoma 60 74
Mrcls 54 60
Liposarcoma Myxoid 56
Myxoliposarcoma 54
Mxlipo 76

Characteristics:

Orphanet epidemiological data:

60
liposarcoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;
myxoid/round cell liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

HPO:

33
myxoid liposarcoma:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:5363
OMIM 58 613488
KEGG 38 H00049
MeSH 45 D018208
SNOMED-CT 69 27849002
MESH via Orphanet 46 D008080 D018208
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0023827 C0206634
MedGen 43 C0206634

Summaries for Myxoid Liposarcoma

NIH Rare Diseases : 54 Myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body�??s fat tissue. Other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. Round cell and myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (MRCLS). In adults, liposarcomas are the most common type of soft tissue sarcoma. The cause of liposarcomas is not well-established but trauma has been implicated in some cases. Myxoid liposarcomas generally arise in the lower extremities. Symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. Many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures. When possible, surgical removal is the preferred treatment. In some cases, additional therapy may be indicated. The prognosis is generally favorable for those with a low grade myxoid liposarcoma with a small percentage of round cells. A significant round cell component is associated with a poorer prognosis.  Although these tumors rarely spread, they can recur if not completely removed. 

MalaCards based summary : Myxoid Liposarcoma, also known as myxoid/round cell liposarcoma, is related to spindle cell liposarcoma and mixed liposarcoma. An important gene associated with Myxoid Liposarcoma is MXLPO (Myxoid Liposarcoma), and among its related pathways/superpathways are Transcriptional misregulation in cancer and ERK Signaling. The drugs Trabectedin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and kidney, and related phenotypes are subcutaneous nodule and abdominal pain

OMIM : 58 Myxoid liposarcoma is a soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion (review by Dei Tos, 2000). (613488)

UniProtKB/Swiss-Prot : 76 Myxoid liposarcoma: A soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion.

Wikipedia : 77 A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance... more...

Related Diseases for Myxoid Liposarcoma

Diseases related to Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 spindle cell liposarcoma 33.7 CDK4 DDIT3 MDM2
2 mixed liposarcoma 33.6 CDK4 DDIT3 FUS MDM2
3 sclerosing liposarcoma 33.6 FUS MDM2 TP53
4 cellular myxoid liposarcoma 33.5 CDK4 EWSR1 FUS HCCS MDM2
5 atypical lipomatous tumor 32.7 CDK4 FUS HMGA2 MDM2
6 liposarcoma 31.1 CDK4 DDIT3 EWSR1 FUS HMGA2 LRP1
7 pleomorphic lipoma 30.9 HMGA2 MDM2
8 lipoblastoma 30.9 CDK4 MDM2
9 myxofibrosarcoma 30.8 FUS MDM2
10 mesenchymoma 30.8 HMGA2 MDM2
11 well-differentiated liposarcoma 30.6 CDK4 HMGA2 MDM2
12 lipomatosis, multiple 30.6 CDK4 FUS HMGA2 MDM2
13 soft tissue sarcoma 30.5 EWSR1 MDM2 TP53
14 infiltrating lipoma 30.4 CDK4 HMGA2 MDM2
15 spindle cell lipoma 30.3 CDK4 MDM2
16 pleomorphic adenoma 30.3 HMGA2 MDM2 TP53
17 malignant mesenchymoma 30.2 CDK4 EWSR1 MDM2 TP53
18 leiomyosarcoma 30.2 CDK4 MDM2 TP53
19 malignant peripheral nerve sheath tumor 30.1 CDK4 MDM2 TP53
20 dedifferentiated liposarcoma 30.0 CDK4 HMGA2 IGF1R MDM2 TP53
21 sarcoma, synovial 30.0 HMGA2 IGF1R MDM2
22 inflammatory myofibroblastic tumor 30.0 CDK4 MDM2 TP53
23 clear cell sarcoma 29.9 ATF1 EWSR1 FUS
24 fibrous histiocytoma 29.9 ATF1 EWSR1 FUS
25 chondroid lipoma 29.8 CDK4 DDIT3 FUS MDM2
26 rhabdomyosarcoma 29.7 CDK4 EWSR1 IGF1R MDM2 TP53
27 sarcomatosis 29.5 ATF1 EWSR1 HMGA2
28 histiocytoma 29.5 ATF1 EWSR1 FUS MDM2 TP53
29 sarcoma 29.1 ATF1 CDK4 DDIT3 ERG EWSR1 FUS
30 myxoid liposarcoma of the ovary 12.7
31 larynx liposarcoma 12.4
32 kidney liposarcoma 12.4
33 pleomorphic liposarcoma 12.3
34 retroperitoneal liposarcoma 12.3
35 gastric liposarcoma 12.2
36 inflammatory liposarcoma 12.2
37 esophagus liposarcoma 12.2
38 cutaneous liposarcoma 12.2
39 liposarcoma of bone 12.2
40 vulvar liposarcoma 12.1
41 pediatric liposarcoma 12.1
42 adult liposarcoma 12.0
43 fibroblastic liposarcoma 12.0
44 intracranial liposarcoma 12.0
45 kidney fibrosarcoma 10.3 EWSR1 HMGA2
46 juxtacortical chondroma 10.3 EWSR1 FUS HMGA2
47 chondrosarcoma, extraskeletal myxoid 10.3 DDIT3 EWSR1 FUS
48 zika virus infection 10.3 MDM2 TP53
49 undifferentiated embryonal sarcoma of the liver 10.3 CDK4 MDM2
50 infiltrating angiolipoma 10.3 CDK4 MDM2

Graphical network of the top 20 diseases related to Myxoid Liposarcoma:



Diseases related to Myxoid Liposarcoma

Symptoms & Phenotypes for Myxoid Liposarcoma

Human phenotypes related to Myxoid Liposarcoma:

60 33 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 subcutaneous nodule 60 33 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001482
2 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002027
3 gastrointestinal dysmotility 60 33 occasional (7.5%) Occasional (29-5%) HP:0002579
4 nausea and vomiting 60 Occasional (29-5%)
5 fatigue 60 Occasional (29-5%)
6 weight loss 60 Occasional (29-5%)
7 paresthesia 60 Occasional (29-5%)
8 abnormality of the kidney 60 Occasional (29-5%)
9 sarcoma 60 Very frequent (99-80%)
10 varicose veins 60 Occasional (29-5%)
11 myxoid liposarcoma 33 HP:0012268

Clinical features from OMIM:

613488

GenomeRNAi Phenotypes related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDK4 CEBPB CXCL8 DDIT3 ERG IGF1R

MGI Mouse Phenotypes related to Myxoid Liposarcoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 CDK4 CEBPB DDIT3 ERG HCCS IGF1R
2 endocrine/exocrine gland MP:0005379 10.02 CDK4 CEBPB DDIT3 ERG IGF1R MDM2
3 hematopoietic system MP:0005397 10.02 CDK4 CEBPB DDIT3 ERG IGF1R LRP1
4 embryo MP:0005380 10.01 CDK4 ERG HCCS IGF1R LRP1 MDM2
5 immune system MP:0005387 9.96 CDK4 CEBPB DDIT3 ERG IGF1R LRP1
6 liver/biliary system MP:0005370 9.7 CDK4 CEBPB DDIT3 IGF1R LRP1 MDM2
7 muscle MP:0005369 9.56 CDK4 CEBPB HCCS IGF1R LRP1 MDM2
8 neoplasm MP:0002006 9.17 CDK4 CEBPB DDIT3 ERG IGF1R MDM2

Drugs & Therapeutics for Myxoid Liposarcoma

Drugs for Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 3,Phase 1,Phase 2 114899-77-3 108150
2
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Epirubicin Approved Phase 3 56420-45-2 41867
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2
10 Alkylating Agents Phase 3,Phase 1,Phase 2
11 Immunologic Factors Phase 3,Phase 2,Phase 1
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2
14 Antibiotics, Antitubercular Phase 3,Phase 2
15 Anti-Bacterial Agents Phase 3,Phase 2
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Etoposide phosphate Phase 3
18 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimitotic Agents Phase 3
20
Isophosphamide mustard Phase 3,Phase 2 0
21 Antimetabolites, Antineoplastic Phase 3
22 Antimetabolites Phase 3
23 Antineoplastic Agents, Phytogenic Phase 3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
26
Mecasermin Approved, Investigational Phase 2 68562-41-4
27
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
28
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
29
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
30
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
31
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
32
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
33
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
34
Pembrolizumab Approved Phase 2 1374853-91-4
35
Mesna Approved, Investigational Phase 2 3375-50-6 598
36
Doxil Approved June 1999 Phase 2 31703
37
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
38
Efatutazone Investigational Phase 2 223132-37-4
39 HIV Protease Inhibitors Phase 2
40 Hormones Phase 2
41 Antineoplastic Agents, Hormonal Phase 2
42 Hormone Antagonists Phase 2
43 Antiemetics Phase 2
44 Anti-Inflammatory Agents Phase 2
45 Gastrointestinal Agents Phase 2
46 Autonomic Agents Phase 2
47 glucocorticoids Phase 2
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
49 BB 1101 Phase 2
50
protease inhibitors Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
2 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
3 Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Unknown status NCT02275286 Phase 1, Phase 2 Trabectedin
4 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
5 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
6 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Completed NCT02609984 Phase 2
7 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
8 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Completed NCT01692496 Phase 2 Pazopanib
9 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
10 Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas Recruiting NCT02106312 Phase 2
11 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
12 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 2
13 Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Recruiting NCT03063632 Phase 2
14 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
15 Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial) Active, not recruiting NCT03816475 Phase 2
16 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Active, not recruiting NCT02249949 Phase 2 efatutazone
17 Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Suspended NCT03397186 Phase 2 Trabectedin
18 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
19 Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Completed NCT01477021 Phase 1 cyclophosphamide
20 Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma Recruiting NCT03450122 Phase 1 Cyclophosphamide;Immunotherapeutic Combination Product CMB305
21 NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Recruiting NCT03399448 Phase 1 Cyclophosphamide;Fludarabine
22 MAGE-A4ᶜ¹º³²T for Multi-Tumor Recruiting NCT03132922 Phase 1
23 Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Not yet recruiting NCT03670069 Phase 1 Itacitinib
24 NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Withdrawn NCT02059850 Phase 1 Cyclophosphamide
25 Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn NCT02210104 Phase 1 Ipilimumab;Cyclophosphamide
26 Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Active, not recruiting NCT01957709 Not Applicable

Search NIH Clinical Center for Myxoid Liposarcoma

Cochrane evidence based reviews: liposarcoma, myxoid

Genetic Tests for Myxoid Liposarcoma

Genetic tests related to Myxoid Liposarcoma:

# Genetic test Affiliating Genes
1 Myxoid Liposarcoma 30

Anatomical Context for Myxoid Liposarcoma

MalaCards organs/tissues related to Myxoid Liposarcoma:

42
T Cells, Bone, Kidney, Thyroid, Myeloid, Prostate, Ovary

Publications for Myxoid Liposarcoma

Articles related to Myxoid Liposarcoma:

(show top 50) (show all 344)
# Title Authors Year
1
Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma. ( 30420727 )
2019
2
Lipoblastoma-like Tumor of the Vulva, an Important Benign Mimic of Myxoid Liposarcoma. ( 29300200 )
2019
3
Myxoid liposarcoma associated with adalimumab treatment: A case report. ( 30931117 )
2019
4
Calreticulin as A Novel Potential Metastasis-Associated Protein in Myxoid Liposarcoma, as Revealed by Two-Dimensional Difference Gel Electrophoresis. ( 30974841 )
2019
5
Myxoid liposarcoma: it's a hippo's world. ( 30979710 )
2019
6
JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. ( 30650179 )
2019
7
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. ( 30787173 )
2019
8
Requirement for YAP1 signaling in myxoid liposarcoma. ( 30898787 )
2019
9
Short tau inversion recovery magnetic resonance imaging for staging and screening in myxoid liposarcoma. ( 30906124 )
2019
10
Vulvar Myxoid Liposarcoma, an Extremely Rare Diagnosis: A Case Report and Review of Literature. ( 29019868 )
2019
11
Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. ( 29558901 )
2018
12
Single metastasis of myxoid liposarcoma from the thigh to thyroid gland: a case report. ( 29587757 )
2018
13
Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses. ( 29588491 )
2018
14
Successful resection of a giant thoracic myxoid liposarcoma. ( 29667901 )
2018
15
Primary meningeal myxoid liposarcoma with aggressive behavior after recurrence: case report. ( 29915889 )
2018
16
Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution. ( 29977616 )
2018
17
Primary Myxoid Liposarcoma of the Greater Omentum in a Rhesus Macaque (Macaca mulatta). ( 30071917 )
2018
18
About a case of paratesticular myxoid liposarcoma. ( 30155408 )
2018
19
Positron emission tomography/computed tomography manifestations of primary hepatic myxoid liposarcoma: A case report. ( 30278507 )
2018
20
Giant myxoid liposarcoma of the gluteal region: case report of patient caused delay of surgical treatment and review of the literature. ( 30310650 )
2018
21
Solitary pancreatic metastasis of extremity myxoid liposarcoma: a case report and literature review. ( 30445938 )
2018
22
A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma. ( 30468937 )
2018
23
Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy. ( 30515050 )
2018
24
Unusual subcutaneous invasion of myxoid liposarcoma. ( 29168208 )
2018
25
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway. ( 29190494 )
2018
26
Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma. ( 29275455 )
2018
27
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. ( 29280411 )
2018
28
Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome. ( 28160093 )
2017
29
MRI characteristics associated with high-grade myxoid liposarcoma. ( 28256200 )
2017
30
Resectable primary pleural myxoid liposarcoma with a pedicle: report of a rare case and literature review. ( 28449500 )
2017
31
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. ( 28637688 )
2017
32
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. ( 28654818 )
2017
33
Unusual Asymptomatic Fluorodeoxyglucose Avid Pheochromocytoma in a Case of Myxoid Liposarcoma of the Extremity on 18-F Fluorodeoxyglucose Positron Emission Tomography-computed Tomography. ( 28670184 )
2017
34
Extensive left ventricular, pulmonary artery, and pericardial metastasis from myxoid liposarcoma 16 years after the initial detection of the primary tumour: a case report and review of the literature. ( 28866706 )
2017
35
Primary Myxoid Liposarcoma of the Upper Thoracic Spine in an Elderly Patient. ( 28936087 )
2017
36
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. ( 28947876 )
2017
37
Myxoid liposarcoma with cartilaginous differentiation showing DDIT3 rearrangement. ( 29181103 )
2017
38
Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma. ( 27511215 )
2017
39
PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24. ( 28192118 )
2017
40
The co-existence of a myxoid liposarcoma and leiomyoma in the same ovarian mass of a dog. ( 26522811 )
2016
41
Lipoblastoma presenting as a rapidly growing paravertebral mass and masquerading as myxoid liposarcoma on fine needle aspiration cytology. ( 26919610 )
2016
42
Soft tissue uptake of 99mTc-MDP in a case of myxoid liposarcoma with breast metastasis. ( 28292146 )
2016
43
Myxoid Liposarcoma Originating In The Anterior Mediastinum. ( 28828769 )
2016
44
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. ( 26897615 )
2016
45
Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. ( 27026512 )
2016
46
Cystic Pulmonary Myxoid Liposarcoma Mimicking Endobronchial Blood Clot. ( 27058719 )
2016
47
miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. ( 27157622 )
2016
48
Primary lesser sac myxoid liposarcoma: A case report. ( 27176503 )
2016
49
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. ( 27270875 )
2016
50
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. ( 27401457 )
2016

Variations for Myxoid Liposarcoma

Cosmic variations for Myxoid Liposarcoma:

9 (show top 50) (show all 217)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6933566 ZFHX3 soft tissue,fat,liposarcoma,NS c.7624T>C p.F2542L 16:72795058-72795058 0
2 COSM6978413 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 0
3 COSM6922065 YES1 soft tissue,fat,liposarcoma,NS c.166A>G p.S56G 18:756662-756662 0
4 COSM3054546 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 0
5 COSM6987297 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.223G>A p.E75K 11:32434919-32434919 0
6 COSM6986268 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 0
7 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 0
8 COSM10646 TP53 soft tissue,fat,liposarcoma,NS c.725G>A p.C242Y 17:7674238-7674238 0
9 COSM44723 TP53 soft tissue,fat,liposarcoma,NS c.674T>C p.V225A 17:7674289-7674289 0
10 COSM44094 TP53 soft tissue,fat,liposarcoma,NS c.716A>G p.N239S 17:7674247-7674247 0
11 COSM10659 TP53 soft tissue,fat,liposarcoma,NS c.817C>T p.R273C 17:7673803-7673803 0
12 COSM10648 TP53 soft tissue,fat,liposarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 0
13 COSM10672 TP53 soft tissue,fat,liposarcoma,pleomorphic c.577C>T p.H193Y 17:7674954-7674954 0
14 COSM43663 TP53 soft tissue,fat,liposarcoma,NS c.826G>C p.A276P 17:7673794-7673794 0
15 COSM10941 TP53 soft tissue,fat,liposarcoma,NS c.730G>A p.G244S 17:7674233-7674233 0
16 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 17:7675208-7675208 0
17 COSM44512 TP53 soft tissue,fat,liposarcoma,NS c.740A>G p.N247S 17:7674223-7674223 0
18 COSM10656 TP53 soft tissue,fat,liposarcoma,pleomorphic c.742C>T p.R248W 17:7674221-7674221 0
19 COSM45794 TP53 soft tissue,fat,liposarcoma,pleomorphic c.421T>G p.C141G 17:7675191-7675191 0
20 COSM11059 TP53 soft tissue,fat,liposarcoma,NS c.713G>A p.C238Y 17:7674250-7674250 0
21 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 17:7674891-7674891 0
22 COSM10654 TP53 soft tissue,fat,liposarcoma,NS c.637C>T p.R213* 17:7674894-7674894 0
23 COSM11245 TP53 soft tissue,fat,liposarcoma,NS c.430C>T p.Q144* 17:7675182-7675182 0
24 COSM43632 TP53 soft tissue,fat,liposarcoma,pleomorphic c.493C>T p.Q165* 17:7675119-7675119 0
25 COSM10731 TP53 soft tissue,fat,liposarcoma,pleomorphic c.707A>G p.Y236C 17:7674256-7674256 0
26 COSM6901 TP53 soft tissue,fat,liposarcoma,NS c.559+1G>A p.? 17:7675052-7675052 0
27 COSM4465309 TNFAIP3 soft tissue,fat,liposarcoma,NS c.1376C>T p.S459L 6:137878821-137878821 0
28 COSM6848516 TET2 soft tissue,fat,liposarcoma,myxoid-round cell c.3809C>T p.T1270I 4:105259624-105259624 0
29 COSM6924539 SMARCA4 soft tissue,fat,liposarcoma,NS c.3940G>T p.D1314Y 19:11034189-11034189 0
30 COSM7002390 SETD2 soft tissue,fat,liposarcoma,NS c.4604C>T p.T1535I 3:47062343-47062343 0
31 COSM6921522 SDHA soft tissue,fat,liposarcoma,myxoid-round cell c.664T>G p.L222V 5:228227-228227 0
32 COSM6942711 ROS1 soft tissue,fat,liposarcoma,NS c.1453T>C p.S485P 6:117389656-117389656 0
33 COSM1437480 RICTOR soft tissue,fat,liposarcoma,pleomorphic c.3404C>T p.T1135M 5:38950444-38950444 0
34 COSM6967634 RBM10 soft tissue,fat,liposarcoma,NS c.443A>G p.Q148R 23:47173138-47173138 0
35 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 13:48456207-48456207 0
36 COSM6966300 RB1 soft tissue,fat,liposarcoma,pleomorphic c.2632G>A p.D878N 13:48476812-48476812 0
37 COSM6906362 RAF1 soft tissue,fat,liposarcoma,pleomorphic c.1141G>A p.D381N 3:12591760-12591760 0
38 COSM5106 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.335T>C p.L112P 10:87933094-87933094 0
39 COSM5135 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.106G>A p.G36R 10:87894051-87894051 0
40 COSM5039 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.518G>A p.R173H 10:87952143-87952143 0
41 COSM1167954 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.485A>T p.D162V 10:87933244-87933244 0
42 COSM5198 PTEN soft tissue,fat,liposarcoma,NS c.72C>G p.D24E 10:87864541-87864541 0
43 COSM3416650 POLE soft tissue,fat,liposarcoma,myxoid-round cell c.2275C>T p.R759C 12:132667547-132667547 0
44 COSM6987724 PLK2 soft tissue,fat,liposarcoma,myxoid-round cell c.1337G>C p.R446P 5:58456073-58456073 0
45 COSM6967036 PLCG2 soft tissue,fat,liposarcoma,NS c.3232C>T p.R1078* 16:81938834-81938834 0
46 COSM2155617 PIK3R1 soft tissue,fat,liposarcoma,NS c.1135A>G p.K379E 5:68293319-68293319 0
47 COSM12458 PIK3CA soft tissue,fat,liposarcoma,NS c.1634A>C p.E545A 3:179218304-179218304 0
48 COSM775 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3140A>G p.H1047R 3:179234297-179234297 0
49 COSM760 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1624G>A p.E542K 3:179218294-179218294 0
50 COSM754 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1035T>A p.N345K 3:179203765-179203765 0

Expression for Myxoid Liposarcoma

Search GEO for disease gene expression data for Myxoid Liposarcoma.

Pathways for Myxoid Liposarcoma

Pathways related to Myxoid Liposarcoma according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 ATF1 CDK4 CEBPB CXCL8 DDIT3 IGF1R
2
Show member pathways
13 CDK4 CEBPB CXCL8 HMGA2 MDM2 TP53
3
Show member pathways
12.76 CDK4 ERG IGF1R MDM2 TP53
4 12.61 CDK4 CXCL8 IGF1R MDM2 TP53 WNT1
5 12.32 CDK4 CEBPB TP53 WNT1
6 12.31 ERG EWSR1 FUS HMGA2
7
Show member pathways
12.24 CEBPB IGF1R MDM2 TP53
8 12.23 ATF1 CDK4 TP53 WNT1
9
Show member pathways
12.18 ATF1 CEBPB CXCL8 TP53
10 12.14 IGF1R MDM2 TP53 WNT1
11
Show member pathways
12.09 CDK4 IGF1R MDM2 TP53
12 12 CDK4 CXCL8 MDM2 TP53
13 11.97 CDK4 IGF1R MDM2 TP53
14 11.95 ATF1 CDK4 MDM2 TP53
15 11.9 CDK4 CXCL8 TP53
16
Show member pathways
11.87 CDK4 CEBPB TP53 WNT1
17 11.86 MDM2 TP53 WNT1
18 11.73 CDK4 MDM2 TP53
19 11.71 CDK4 IGF1R MDM2 TP53
20 11.67 ATF1 CEBPB CXCL8 DDIT3 ERG EWSR1
21 11.66 CXCL8 MDM2 TP53
22 11.58 CEBPB CXCL8 IGF1R MDM2 TP53
23 11.49 CDK4 CXCL8 MDM2 TP53
24 11.44 CDK4 CXCL8 DDIT3
25 11.3 CDK4 MDM2 TP53
26 11.22 ATF1 CDK4 MDM2 TP53
27 11.11 CDK4 MDM2 TP53
28 10.89 LRP1 WNT1
29 10.8 ATF1 CEBPB DDIT3 TP53

GO Terms for Myxoid Liposarcoma

Cellular components related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle membrane GO:0030666 9.13 LRP1 MDM2 WNT1
2 CHOP-C/EBP complex GO:0036488 8.62 CEBPB DDIT3

Biological processes related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 CEBPB DDIT3 HMGA2 TP53 WNT1
2 negative regulation of apoptotic process GO:0043066 9.88 HMGA2 IGF1R MDM2 TP53 WNT1
3 negative regulation of transcription, DNA-templated GO:0045892 9.85 CEBPB DDIT3 HMGA2 MDM2 TP53
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 ATF1 CEBPB DDIT3 ERG HMGA2 TP53
5 regulation of transcription, DNA-templated GO:0006355 9.76 ATF1 CEBPB DDIT3 ERG EWSR1 FUS
6 response to endoplasmic reticulum stress GO:0034976 9.5 CEBPB CXCL8 DDIT3
7 amyloid-beta clearance GO:0097242 9.43 IGF1R LRP1
8 PERK-mediated unfolded protein response GO:0036499 9.4 CXCL8 DDIT3
9 ER overload response GO:0006983 9.37 DDIT3 TP53
10 transcription by RNA polymerase II GO:0006366 9.19 CEBPB
11 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
12 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 8.8 CEBPB DDIT3 TP53

Molecular functions related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ATF1 EWSR1 FUS IGF1R MDM2 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.35 CEBPB DDIT3 ERG HMGA2 TP53
3 transcription regulatory region DNA binding GO:0044212 9.02 CEBPB DDIT3 HMGA2 TP53 WNT1

Sources for Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....